Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist

GLP-1 has a variety of anti-diabetic effects. However, native GLP-1 is not suitable for therapy of diabetes due to its short half-life (t1/2<2 min). To circumvent this, we developed a long-lasting GLP-1 receptor agonist by the fusion of GLP-1 with human IgG2 Fc (GLP-1/hIgG2). ELISA-based receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qinghua, Chen, Kui, Liu, Rui, Zhao, Fang, Gupta, Sandeep, Zhang, Nina, Prud'homme, Gerald J.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939854/
https://www.ncbi.nlm.nih.gov/pubmed/20856794
http://dx.doi.org/10.1371/journal.pone.0012734

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939854/
https://www.ncbi.nlm.nih.gov/pubmed/20856794
http://dx.doi.org/10.1371/journal.pone.0012734

Ejemplares similares